LP-1890

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameLP-1890
Drug Alias Nameallosteric p38 MAP kinase alpha inhibitors (Locus/Ansaris)allosteric p38 inhibitors (Locus/Ansaris)allosteric p38 MAP kinase alpha/beta inhibitors (Locus/Ansaris)LP-1790LOC-985 +[6] 
ClassificationSmall molecules
Mechanisms of ActionAngiogenesis inhibitorsP38 α mitogen-activated protein kinase inhibitorsAnticancer protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsInflammationEye DiseasesArthritis, Rheumatoid +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLocus
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAnsaris IncLocus
Active IndicationsN/A
Inactive IndicationsInflammationEye DiseasesArthritis, Rheumatoid +[5] 

Other Information

ATC CodeN/A
Related LinksN/A